127 related articles for article (PubMed ID: 28626861)
1. Diphenylcyclopropenone for the treatment of cutaneous in-transit melanoma metastases - results of a prospective, non-randomized, single-centre study.
Read T; Webber S; Tan J; Wagels M; Schaider H; Soyer HP; Smithers BM
J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):2030-2037. PubMed ID: 28626861
[TBL] [Abstract][Full Text] [Related]
2. Topical diphencyprone immunotherapy for cutaneous metastatic melanoma.
Damian DL; Shannon KF; Saw RP; Thompson JF
Australas J Dermatol; 2009 Nov; 50(4):266-71. PubMed ID: 19916970
[TBL] [Abstract][Full Text] [Related]
3. Responses to Topical Diphenylcyclopropenone as an Adjunct Treatment for In-Transit Melanoma: A Tertiary Referral Center Experience.
Veverka KK; Jakub JW; Baum CL
Dermatol Surg; 2018 Dec; 44(12):1501-1508. PubMed ID: 29985863
[TBL] [Abstract][Full Text] [Related]
4. Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases-a phase II, single centre, randomised, pilot study.
Read T; Webber S; Thomas J; Wagels M; Schaider H; Soyer HP; Smithers BM
BMJ Open; 2017 Oct; 7(10):e016816. PubMed ID: 28988173
[TBL] [Abstract][Full Text] [Related]
5. Sequencing in management of in-transit melanoma metastasis: Diphencyprone versus isolate limb infusion.
Lo MC; Garioch J; Moncrieff MD
J Plast Reconstr Aesthet Surg; 2020 Jul; 73(7):1263-1267. PubMed ID: 32245735
[TBL] [Abstract][Full Text] [Related]
6. Topical immunotherapy with diphencyprone (DPCP) for in-transit and unresectable cutaneous melanoma lesions: an inaugural Canadian series.
Yeung C; Petrella TM; Wright FC; Abadir W; Look Hong NJ
Expert Rev Clin Immunol; 2017 Apr; 13(4):383-388. PubMed ID: 28121191
[TBL] [Abstract][Full Text] [Related]
7. Diphencyprone as a therapeutic option in cutaneous metastasis of melanoma. A single-institution experience.
Gibbons IL; Sonagli M; Bertolli E; Macedo MP; Pinto CAL; Duprat Neto JP
An Bras Dermatol; 2018 Mar; 93(2):299-301. PubMed ID: 29723355
[TBL] [Abstract][Full Text] [Related]
8. Lesional therapies for in-transit melanoma.
Nadler A; Look Hong NJ; Alavi N; Abadir W; Wright FC
J Surg Oncol; 2020 Nov; 122(6):1050-1056. PubMed ID: 32668038
[TBL] [Abstract][Full Text] [Related]
9. Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment.
Gulati N; Carvajal RD; Postow MA; Wolchok JD; Krueger JG
Exp Dermatol; 2016 Jul; 25(7):553-4. PubMed ID: 27061281
[No Abstract] [Full Text] [Related]
10. Congenital malignant melanoma and cutaneous metastases treated with diphencyprone.
Fawcett JM; Newell EL; Kennedy CT
Clin Exp Dermatol; 2016 Mar; 41(2):212-3. PubMed ID: 26053880
[No Abstract] [Full Text] [Related]
11. Treatment of extensive cutaneous metastatic melanoma with topical diphencyprone.
Damian DL; Thompson JF
J Am Acad Dermatol; 2007 May; 56(5):869-71. PubMed ID: 17276544
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled study of electrochemotherapy in the local treatment of skin metastases of melanoma.
Gaudy C; Richard MA; Folchetti G; Bonerandi JJ; Grob JJ
J Cutan Med Surg; 2006; 10(3):115-21. PubMed ID: 17241586
[TBL] [Abstract][Full Text] [Related]
13. Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma.
Damian DL; Saw RP; Thompson JF
J Surg Oncol; 2014 Mar; 109(4):308-13. PubMed ID: 24522938
[TBL] [Abstract][Full Text] [Related]
14. Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population.
Aghaei S
BMC Dermatol; 2005 May; 5():6. PubMed ID: 15918897
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: a retrospective case series.
Durdu M; Özcan D; Baba M; Seçkin D
J Am Acad Dermatol; 2015 Apr; 72(4):640-50. PubMed ID: 25653027
[TBL] [Abstract][Full Text] [Related]
16. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma.
Bong AB; Bonnekoh B; Franke I; Schön M; Ulrich J; Gollnick H
Dermatology; 2002; 205(2):135-8. PubMed ID: 12218228
[TBL] [Abstract][Full Text] [Related]
17. Diphenylcyclopropenone (diphencyprone, DPCP) in the treatment of chronic severe alopecia areata (AA).
Galadari I; Rubaie S; Alkaabi J; Galadari H
Eur Ann Allergy Clin Immunol; 2003 Dec; 35(10):397-401. PubMed ID: 14768526
[TBL] [Abstract][Full Text] [Related]
18. Intra-lesional interleukin-2 for the treatment of in-transit melanoma.
Boyd KU; Wehrli BM; Temple CL
J Surg Oncol; 2011 Dec; 104(7):711-7. PubMed ID: 21744347
[TBL] [Abstract][Full Text] [Related]
19. Case report: Regression of in-transit metastases of cutaneous squamous cell carcinoma with combination pembrolizumab and topical diphencyprone.
Poplausky D; Young JN; Block BR; Estrada Y; Singer GK; Wong V; Cabral P; Suemitsu Y; Kim RH; Friedlander P; Gulati N
Front Oncol; 2024; 14():1294331. PubMed ID: 38800408
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases.
Radny P; Caroli UM; Bauer J; Paul T; Schlegel C; Eigentler TK; Weide B; Schwarz M; Garbe C
Br J Cancer; 2003 Nov; 89(9):1620-6. PubMed ID: 14583759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
